Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Maze Therapeutics, Inc. has received an average rating of "Buy" from analysts, with five analysts recommending a buy and two issuing strong buy ratings.
• The company's stock recently opened at $14.05, up 5.6%, and has a 1-year target price averaging $25.60 based on broker reports.
• Institutional investors have significantly increased their stakes in Maze Therapeutics, with notable new investments from firms like TRV GP IV LLC and Alphabet Inc..

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus recommendation of "Buy" by the seven ratings firms that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $25.60.

MAZE has been the subject of a number of recent research reports. HC Wainwright initiated coverage on shares of Maze Therapeutics in a research report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price target for the company. Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Finally, Wedbush initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target for the company.

Maze Therapeutics Stock Performance

MAZE traded up $0.22 during trading on Wednesday, reaching $14.49. 358,404 shares of the company's stock were exchanged, compared to its average volume of 285,479. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $19.19. The company's fifty day simple moving average is $14.25 and its 200-day simple moving average is $11.93.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its holdings in shares of Maze Therapeutics by 452.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock valued at $57,000 after purchasing an additional 3,774 shares in the last quarter. Frazier Life Sciences Management L.P. increased its holdings in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after purchasing an additional 438,274 shares in the last quarter. Engineers Gate Manager LP purchased a new position in shares of Maze Therapeutics during the 2nd quarter valued at approximately $125,000. Bank of America Corp DE increased its holdings in shares of Maze Therapeutics by 33.6% during the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock valued at $71,000 after purchasing an additional 1,455 shares in the last quarter. Finally, CW Advisors LLC purchased a new position in shares of Maze Therapeutics during the 2nd quarter valued at approximately $371,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.